Microangiopathy

MemorialCare Launches New Women's Heart Center and Recruits Nissi Suppogu, M.D. as Medical Director - Creating Sub-Specialized Women's Heart Health Center in Community

Retrieved on: 
Thursday, February 1, 2024
Cardiology, Anxiety, Microangiopathy, Hypertension, Long Beach Medical Center, Family, Artery, Obesity, Heart, Chronic pain, Cardiovascular disease, Gestational diabetes, Research, Exercise, Patient, Splenic infarction, Diagnosis, Scar, Friends, Autoimmune disease, Chest pain, Catheter, Depression, Pregnancy, Neck, Physician, Vasospasm, Diabetes, Dizziness, Education, Risk, Menopause, Smoking, Blood, Rest, Health, Place of birth, Fatigue, Human, Rehabilitation

FOUNTAIN VALLEY, Calif., Feb. 1, 2024 /PRNewswire/ -- MemorialCare, a prominent nonprofit Southern California integrated health system, has announced the launch of the Women's Heart Center at the MemorialCare Heart & Vascular Institute – a specialized center dedicated solely to expertise in education, prevention, early diagnosis, and timely management of women-specific cardiac presentations across their lifespan. The Women's Heart Center's first site will be in conjunction with Long Beach Medical Center and MemorialCare Medical Group, with future plans to expand to additional MemorialCare sites in Orange County.

Key Points: 
  • The Women's Heart Center's first site will be in conjunction with Long Beach Medical Center and MemorialCare Medical Group , with future plans to expand to additional MemorialCare sites in Orange County.
  • To lead a dynamic and distinctive program such as this, MemorialCare has recruited and appointed Nissi Suppogu, M.D.
  • as the medical director of the Women's Heart Center.
  • Dr. Suppogu is fellowship trained, meaning she has two years of additional sub-specialty training and education in women's heart health.

Three Journal of Pharmaceutical Analysis Studies Explore the Use of Traditional Chinese Medicine for Various Diseases

Retrieved on: 
Friday, January 26, 2024
DMY, Microangiopathy, Neoplasm, VEGF, NAFLD, Radiation, Fe, ATGL, Disease, Lung cancer, TCM, DR, Risk, Quality of life, Diabetic retinopathy, Journal, Nano, Traditional Chinese medicine, Liver, Noetics, Protein, HSP90, CDC37, Non-alcoholic fatty liver disease, Iron

XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.

Key Points: 
  • XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.
  • To address this gap, a new issue of the Journal of Pharmaceutical Analysis presents three independent studies which assessed the potency of TCM-based compounds for various human diseases, along with their molecular mechanisms of action.
  • Oridonin (ORI), a TCM derived from the Chinese herb Rabdosia rubescens, exhibits anti-inflammatory effects.
  • These studies provide a scientific basis for the development of TCM-based compounds into effective targeted therapies for various diseases.

Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Study in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at the 2023 ASH Annual Meeting

Retrieved on: 
Thursday, December 14, 2023
Safety, Interim, ASH, Cohort, Headache, PD, PNH, Patient, ULN, IgA nephropathy, Week, Microangiopathy, Pharmacokinetics, Immunoglobulin A, COVID19, Common, Society, RBC, LDH, Medical device, Pharmaceutical industry, Fine chemical, Vaccine

The interim results support the advancement of KP104 to Phase 3 studies as an optimal and safe treatment for PNH patients to address currently unmet medical needs.

Key Points: 
  • The interim results support the advancement of KP104 to Phase 3 studies as an optimal and safe treatment for PNH patients to address currently unmet medical needs.
  • The presentation has also been selected to be featured in the 2024 Highlights of ASH.
  • Kira Pharmaceuticals is committed to advancing KP104 as an innovative therapy for patients with PNH and other complement-mediated diseases.
  • Title: KP104, a bifunctional C5 antibody/factor H fusion protein, effectively controls both intravascular and extravascular hemolysis: interim results from a phase 2 study in complement inhibitor-naïve PNH patients

CorFlow Announces Positive Data from the MOCA I First in Human Study Presented at EuroPCR 2023

Retrieved on: 
Friday, May 19, 2023
Science, Cardiology, Biotechnology, Research, Health, Medical Devices, Hospitals, Clinical Trials, Montefiore Medical Center, Myocardial infarction, Heart failure, Stroke, Reflow soldering, Splenic infarction, STEMI, PPCI, Multimedia, Cardiovascular disease, PCI, MVO, MRI, Professor, Magnetic resonance, Patient, AUC, MOCA, Mortality, Death, Microangiopathy, Safety, Pharmaceutical industry, Medical imaging, COFI

The data set presented in a EuroPCR Late Breaking Trial session included 30 patients with an ST elevation myocardial infarction (STEMI), the most severe type of heart attack.

Key Points: 
  • The data set presented in a EuroPCR Late Breaking Trial session included 30 patients with an ST elevation myocardial infarction (STEMI), the most severe type of heart attack.
  • View the full release here: https://www.businesswire.com/news/home/20230519005005/en/
    CorFlow has developed a next-generation fully-integrated CoFI system, which will be utilized in the upcoming pivotal trial prior to be commercially available.
  • It is an investigational device limited by federal law to investigational use and is not available for commercial distribution yet.
  • MOCA I shows that we can, and will, do better for these patients.”

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

Retrieved on: 
Monday, May 1, 2023
Stent, Small Vessel, Investigational device exemption, Cardiac muscle, PTA, Restenosis, CAD, ISR, Revascularization, MACE, Trial of the century, PCI, Microangiopathy, Sirolimus, PMA, Patient, Physician, Risk, IDE, Coronary artery disease, FDA, SCB, Cutaneous small-vessel vasculitis, Drug-eluting stent, US FDA, Safety, Pharmaceutical industry, MD, TITAN

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.

Key Points: 
  • TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.
  • US FDA, on the 25th of April 2023, granted the third IDE approval for Concept Medical's Sirolimus Coated Balloon – MagicTouch SCB.
  • Along with this latest IDE approval for the treatment of Small Vessel indication, Concept Medical received two other IDE approvals for the MagicTouch SCB family of products for the treatment of coronary In-Stent Restenosis (ISR) indication and Below-the-Knee indication (PTA).
  • The current IDE approval will allow Concept Medical to initiate pivotal clinical study to support safety and effectiveness of the MagicTouch SCB in small vessel coronary disease.

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

Retrieved on: 
Monday, May 1, 2023
Stent, Small Vessel, Investigational device exemption, Cardiac muscle, PTA, Restenosis, CAD, ISR, Revascularization, MACE, Trial of the century, PCI, Microangiopathy, Sirolimus, PMA, Patient, Physician, Risk, IDE, Coronary artery disease, FDA, SCB, Cutaneous small-vessel vasculitis, Drug-eluting stent, US FDA, Safety, Pharmaceutical industry, MD, TITAN

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.

Key Points: 
  • TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.
  • US FDA, on the 25th of April 2023, granted the third IDE approval for Concept Medical's Sirolimus Coated Balloon – MagicTouch SCB.
  • Along with this latest IDE approval for the treatment of Small Vessel indication, Concept Medical received two other IDE approvals for the MagicTouch SCB family of products for the treatment of coronary In-Stent Restenosis (ISR) indication and Below-the-Knee indication (PTA).
  • The current IDE approval will allow Concept Medical to initiate pivotal clinical study to support safety and effectiveness of the MagicTouch SCB in small vessel coronary disease.

SeqOne Genomics and the French Thrombotic MicroAngiopathies National Reference Center (CNR-MAT) Pioneer the Use of Oxford Nanopore Sequencing Technology to Improve Patient Outcomes in Kidney Disease While Reducing Turnaround Times

Retrieved on: 
Thursday, February 9, 2023
Research, Nursing, Infectious Diseases, Genetics, Biotechnology, Health, Pharmaceutical, Science, Oncology, DNA, Nephrology, Thrombocytopenia, Diagnosis, Patient, DSM-IV codes, Microangiopathy, Oxford Nanopore Technologies, Thrombotic microangiopathy, Vitamin B12, Thrombosis, TMA, Nanopore sequencing, Chelsea Handler, Hypertension, Gene, Disease, Kidney, Prognosis, Multimedia, Oxford, Hemolysis, Genome, Comment (computer programming), Dietary supplement, Medical imaging, Eculizumab

Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS).

Key Points: 
  • Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS).
  • The program involved using Oxford Nanopore’s revolutionary technology to sequence patients at the bedside, dramatically reducing turnaround times to obtaining actionable insights.
  • This Oxford Nanopore-based analysis was compared with traditional short read sequencing approaches in order to establish a benchmark against current standards of care and hence quantify benefits of nanopore sequencing.
  • In order to support the program, SeqOne implemented an Oxford Nanopore compatible long-read support capable of managing adaptive sampling data.

Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test

Retrieved on: 
Monday, January 9, 2023
Health, Neurology, Other Science, Research, Science, Biotechnology, Simoa, Multiple sclerosis, RUO, Blood, Neurodegeneration, CSF, CLIA, Ageing, RRMS, SLAC National Accelerator Laboratory, MS, Laboratory developed test, AFL, HIV, Amyotrophic lateral sclerosis, Corporation, Microangiopathy, LDT, FDA, Risk, Neurology, Plasma, TBI, ISO 15189, Protein, Diagnosis, Central nervous system, CAR, Therapy, Patient, HIV/AIDS, Research, ISO, Stroke, Serum, Nerve, Concussion, Traumatic brain injury, Clinical trial, Cerebrospinal fluid, ALS, Medical device, Pharmaceutical industry, Medical imaging, Parkinsonism

NfL is a well-studied biomarker for neuro-axonal injury with wide applicability to different neurological disorders.

Key Points: 
  • NfL is a well-studied biomarker for neuro-axonal injury with wide applicability to different neurological disorders.
  • Any disorder or injuring force resulting in neuronal damage can lead to the release of NfL into the interstitial fluid and cerebrospinal fluid (CSF).
  • A fraction of these proteins diffuses into the blood, where concentrations are typically 50- to 100-fold lower than in CSF and difficult to measure with conventional immunoassay technologies.
  • “Assessment and monitoring of brain health is incredibly difficult and typically performed in limited fashion by surgery or imaging.

NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Experiment, AST, Company, Chemistry, Risk, Fatigue, Therapy, Phase, FIX, 2021 Essex County Council election, Society, GLOBE, Monoclonal antibody, Safety, Thrombocytopenia, Incidence, ALT, AES, ATD, IND, Microangiopathy, Poster, CRS, Toxicity, Mantle cell lymphoma, Half-life, TCE, APC, HLE, Chronic lymphocytic leukemia, Factor X, CEO, CR, Emicizumab, Nausea, CMC, FX, MCL, Haemophilia, Headache, Hematology, Technology, Drug discovery, Treatment, Patient, ROR1, CLL, Vaccine, Medical device, Pharmaceutical industry

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside an auto-regulation platform, today announces the online publication of three abstracts submitted to the American Society of Hematology Annual meeting, to be held December 10-13, 2022.

Key Points: 
  • Adverse events (AEs) were largely limited to week 1 of cycle 1 and all were reversible.
  • The most common AEs were Grade 1 or 2 nausea (70%), headaches (60%), and fatigue (50%) and thrombocytopenia (30%).
  • Consequently, emicizumab is associated with a high incidence of thromboembolic events and thrombotic microangiopathies, particularly when combined with activated prothrombin complex concentrates.
  • This study heralds a new class of therapeutics for haemophilia A with a self-regulating off switch designed to enhance safety without compromising efficacy.

Modulim Announces Launch of Magnifi Clinical Workflow Software at Kidney Week 2022

Retrieved on: 
Thursday, November 3, 2022
Cloud, Patient, LAMP, HIPAA, Kidney disease, American Society of Nephrology, Kidney, Workflow, CA, Society, Magnifier (Windows), Data management, Ulcer, Standard of care, Assessment, Health, CEO, Chronic kidney disease, Moyamoya disease, Cancer, Risk, Nephrology, ESRD, Hospital, Technology, Ecosystem, Software, Data, Microangiopathy, Solution, Pharmaceutical industry, Medical imaging, Diabetes

IRVINE, Calif., Nov. 3, 2022 /PRNewswire/ -- Modulim, a health technology company that delivers point-of-care microvascular and data insights to save limbs and improve lives, announces the launch of Magnifi at American Society of Nephrology's Kidney Week 2022 in Orlando, FL, a software solution designed to empower clinicians with remote access to data insights and scalability to enhance clinical workflow across enterprises.

Key Points: 
  • The software solution takes a particular clinician's expertise and expands their impact and physical reach by enabling them to care for patients from anywhere.
  • "There are 61 million people in the US at risk for lower limb complications due to Diabetes, Kidney Disease, and Peripheral Arterial Disease.
  • Magnifi software utilizes the HIPAA compliant Modulim Cloud to securely and seamlessly sync with data captured by Clarifi.
  • Magnifi enhances clinical efficiency, improves workflow, and aides clinicians with scalable patient-centric software.